Cancers (Aug 2023)

PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines

  • Elisa González-Romero,
  • Cristina Martínez-Valiente,
  • Gema García-García,
  • Antonio Rosal-Vela,
  • José María Millán,
  • Miguel Ángel Sanz,
  • Guillermo Sanz,
  • Alessandro Liquori,
  • José Vicente Cervera,
  • Rafael P. Vázquez-Manrique

DOI
https://doi.org/10.3390/cancers15174263
Journal volume & issue
Vol. 15, no. 17
p. 4263

Abstract

Read online

Acute myeloid leukemia is a complex heterogeneous disease characterized by the clonal expansion of undifferentiated myeloid precursors. Due to the difficulty in the transfection of blood cells, several hematological models have recently been developed with CRISPR/Cas9, using viral vectors. In this study, we developed an alternative strategy in order to generate CRISPR constructs by fusion PCR, which any lab equipped with basic equipment can implement. Our PCR-generated constructs were easily introduced into hard-to-transfect leukemic cells, and their function was dually validated with the addition of MYBL2 and IDH2 genes into HEK293 cells. We then successfully modified the MYBL2 gene and introduced the R172 mutation into the IDH2 gene within NB4 and HL60 cells that constitutively expressed the Cas9 nuclease. The efficiency of mutation introduction with our methodology was similar to that of ribonucleoprotein strategies, and no off-target events were detected. Overall, our strategy represents a valid and intuitive alternative for introducing desired mutations into hard-to-transfect leukemic cells without viral transduction.

Keywords